So they would tolerate a higher level of adverse events to have treatment effects that were more beneficial.

In practicality, when you mentioned trade-offs, again, I like to emphasize that it's not either medication or multimodal management, they have to work together.

The two of them have to go together or you're not treating the disease.

And now that we have more research and understanding about the importance of brain neuroplasticity on the release of the interaction between the brain and the metabolism and insulin resistance.

And with the GLP-1 agonist, they helped us understand a little more into the biology of obesity.

So when we talk about medications, it's really important that we frame it in this way.

as well as also I think that it helps them to feel, you know, that they're being supported and that they know, the families know that they're not going to be prescribed the medication and then dropped from the program.

Like it's just not funded or there's no one who does it?